95 filings
Page 4 of 5
8-K
f67jz5m0
25 Nov 22
Entry into a Material Definitive Agreement
4:30pm
8-K
rwbnr
15 Nov 22
Allarity Therapeutics Reports Third Quarter 2022 Financial Results
5:00pm
8-K
n8d8iru
7 Nov 22
Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders
6:21pm
8-K
k6deyuq6
14 Oct 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:25pm
8-K
2cqp2wqi
11 Oct 22
Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements
4:15pm
8-K
ujgy1gvn8lmfchxue
30 Sep 22
Entry into a Material Definitive Agreement
4:49pm
8-K
fnhy3n
26 Sep 22
Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors
4:30pm
8-K
ql5rmin1c9 p9xv
12 Sep 22
Allarity Therapeutics Announces Appointment of New Auditor
4:10pm
6-K
k4i6d7zcg
31 Aug 22
Report of Foreign Private Issuer
11:56am
8-K
c8tzx
29 Aug 22
Regulation FD Disclosure
6:30am
8-K
gis0v
26 Aug 22
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance
4:37pm
8-K/A
uzfvkb
24 Aug 22
Changes in Registrant's Certifying Accountant
5:15pm
8-K
fb5z3w cs6
22 Aug 22
Results of Operations and Financial Condition
5:08pm
8-K
ez8t6fw3b5
16 Aug 22
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:01pm
8-K
tv8yho3
12 Aug 22
Entry into a Material Definitive Agreement
5:04pm
8-K
3d9h3esy5
2 Aug 22
Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies
9:33am
8-K
m1un3mqlxxi2g4s
11 Jul 22
Departure of Directors or Certain Officers
4:05pm
8-K
wr9y8nybzu bilgmn
29 Jun 22
Allarity Therapeutics Announces Executive Leadership Transition
7:44pm
8-K
gejk vqr479u2n
10 Jun 22
Entry into a Material Definitive Agreement
4:01pm
8-K
eu4koqwfnkcd59dyej
27 May 22
Allarity Therapeutics Reports First Quarter 2022 Financial Results
5:29pm